Ultime notizie per iTech Minerals (OTC:ITMIF) Azioni

iTech Minerals Ltd is a speculative exploration company. It is an industrial and battery minerals exploration and development company with a focus on Eyre Peninsula Graphite Project, Reynolds Range Project and Eyre Peninsula Kaolin Project.

ITECH MINERALS LTD by ITECH MINERALS LTD.

iTech Minerals Ltd

Earnings

News

SGHC

Super Group Q3 Revenue €402.9M, Profit €8.5M

Leerink Partners analyst Rick Bienkowski upgrades Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) from Market Perform to Outperform and raises the price target from $27 to $39.

Upgrades

Price Target

Analyst Ratings

BEAM

Leerink Partners Upgrades Beam Therapeutics to Outperform, Raises Price Target to $39

DJT: 61% &#x7C; <a href="https://www.benzinga.com//node/41769412">Dow, Nasdaq Futures Race Higher As Trump Wins White House: DJT, Tesla Shares Surge — Veteran Investor Predicts US Economy Could 'Take Off'</a>
&nbsp;
QLYS: 20% &#x7C; <a href="https://www.benzinga.com//node/41770315">Qualys shares are trading higher after the company reported better-than-expected Q3 financial results, raised its FY24 guidance, and issued Q4 revenue guidance above estimates.</a>
&nbsp;
PACS: -23% &#x7C; <a href="https://www.benzinga.com//node/41768760">PACS Group shares are trading lower after the company announced postponement of Q3 results and disclosure on civil investigative demands from the federal government.</a>

Movers

Trading Ideas

PACS

QLYS

Market-Moving News for November 6th

Morgan Stanley analyst James Quigley maintains Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) with a Equal-Weight and raises the price target from $45 to $49.

KYMR

Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $49

Morgan Stanley analyst Judah Frommer maintains Arcellx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) with a Overweight and raises the price target from $81 to $106.

ACLX

Morgan Stanley Maintains Overweight on Arcellx, Raises Price Target to $106

Morgan Stanley analyst Vincent Andrews maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Equal-Weight and lowers the price target from $140 to $100.

Morgan Stanley Maintains Equal-Weight on Celanese, Lowers Price Target to $100

JP Morgan analyst Lisa Gill reinstates PACS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) with a Overweight and announces $40 price target.

Initiation

JP Morgan Reinstates Overweight on PACS Group, Announces $40 Price Target

Guidance

FOLD

Amicus Therapeutics Raises 2024 Total Revenue Growth Guidance From 26% - 31% To 30% - 32% At CER

HC Wainwright &amp; Co. analyst Robert Burns reiterates Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) with a Neutral and maintains $4 price target.

Reiteration

MGNX

HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $4 Price Target

WW International Reiterates FY24 Outlook: Sees Revenue Of At Least $770.0M Vs. $775.46M Estimate

Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(1.16) by 37.93 percent. The company reported quarterly sales of $134.00 million which beat the analyst consensus estimate of $130.13 million by 2.97 percent. This is a 6.94 percent decrease over sales of $144.00 million the same period last year.

IONS

Ionis Pharmaceuticals Q3 2024 Adj EPS $(0.72) Beats $(1.16) Estimate, Sales $134.00M Beat $130.13M Estimate

Morgan Stanley analyst Hamza Fodderwala maintains Qualys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) with a Underweight and raises the price target from $123 to $126.

Morgan Stanley Maintains Underweight on Qualys, Raises Price Target to $126

Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) reported quarterly earnings of $1.04 per share which beat the analyst consensus estimate of $0.93 by 11.83 percent. The company reported quarterly sales of $565.00 million which missed the analyst consensus estimate of $696.10 million by 18.83 percent. This is a 5.41 percent increase over sales of $536.00 million the same period last year.

Earnings Beats

RPRX

Royalty Pharma Q3 2024 Adj EPS $1.04 Beats $0.93 Estimate

Morgan Stanley analyst Michael Cyprys downgrades Cboe Global Markets (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) from Equal-Weight to Underweight and announces $199 price target.

Downgrades

CBOE

Morgan Stanley Downgrades Cboe Global Markets to Underweight, Announces $199 Price Target

JP Morgan analyst Samik Chatterjee downgrades Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) from Neutral to Underweight and lowers the price target from $50 to $23.

SMCI

JP Morgan Downgrades Super Micro Computer to Underweight, Lowers Price Target to $23

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.29) by 55.17 percent. This is a 124.53 percent decrease over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $33.23 million which beat the analyst consensus estimate of $30.40 million by 9.32 percent. This is a 18.80 percent increase over sales of $27.97 million the same period last year.

Comments

iTech Minerals

Notizie

Ultime notizie per iTech Minerals (OTC:ITMIF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO